TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.160nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.390nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.440nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.780nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 43nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 73nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 90nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 130nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 207nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 450nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 930nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 47(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >2.00E+3nMAssay Description:Inhibition of USP47 (unknown origin) by biochemical assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.70E+3nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.20E+3nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 47(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >5.00E+3nMAssay Description:Inhibition of USP47 (unknown origin) by biochemical assayMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5.60E+3nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8.00E+3nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8.20E+3nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human DAC-tagged USP27X expressed in Escherichia coli assessed as cleavage of KI63-linked di-ubiquitin to mono-ubiquitin using di-ubiqu...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 2(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human GST-tagged USP2 isoform 4 expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and R...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 15(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human USP15 isoform 2 expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine11...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 4(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human 6His-tagged USP4 expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine1...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human GST-tagged USP6 CD (529 to 1406 residues) expressed in Sf21 insect cells assessed as cleavage of Ubiquitin-Rhodamine110-glycine t...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 8(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human USP8 expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine110-glycine u...More data for this Ligand-Target Pair
TargetProbable ubiquitin carboxyl-terminal hydrolase FAF-X(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human GST-tagged USP9X CD (1554 to 1995 residues) expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine ...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of USP11 (unknown origin)More data for this Ligand-Target Pair